JAK inhibitors

money flying in

Biotech

Minghui raises $131M to fund JAK inhibitor launch, ADC trials

Minghui has secured $131 million for what the company describes as a “pre-IPO” round to fuel the potential launch of its eye drug in China.

James Waldron Aug 7, 2025 8:15am

photo of a pair of binoculars perched on a rock aimed at the rising sun

Fierce Pharma

New Incyte CEO takes 'fresh look' at business, outlines BD plan

Aug 4, 2025 11:16am

target reach ladder climb meet win beat competition

Soterios looks to ph. 3 after win for alopecia areata cream

May 30, 2024 8:14am

An arrow incrementally going up stairs before pointing straight up Blue background

Incyte's oral Dupixent rival hits in midphase skin disease trial

Mar 11, 2024 7:16am

Takeda

How Takeda beat the rest of the industry to snag Nimbus' TYK2

Jan 11, 2024 10:30am

layoff layoffs staff

Aclaris lays off 46%, resurrects zunsemetinib for cancer

Dec 20, 2023 6:09am